A study from the Department of Cell & Molecular Biology, Pontificia Universidad Católica de Chile, Santiago 8331010, Chile; and Biological and Chemistry Sciences Department, Universidad Bernardo O’Higgins, Santiago 8370993, Chile shows that “c-Abl Stabilizes HDAC2 Levels … Neuronal Gene Expression in Alzheimer’s Disease.”
This study was published in the 9 September, 2014 Molecular Cell by Prof. Alvarez AR, Gonzalez-Zuñiga M [I.F ~ 15.324] and others from the Pontificia Universidad Católica de Chile, Santiago 8331010, Chile; and Biological and Chemistry Sciences Department, Universidad Bernardo O’Higgins, Santiago 8370993, Chile.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: MiRNA-based treatment for Alzheimer’s Disease: MiRNA-4723 decreases HDAC2 levels and increases the expression of synaptic genes via down regulation of its target gene. This study may suggest that MiRNA-4723, by down regulating its target gene, it may induce the expression of synaptic genes. Thereby, it may inhibit the progression of alzheimer’s disease. Together, this study suggests that pharmacological formulations encompassing “MiRNA-4723 or its activators“ may be used in the treatment of Alzheimer’s disease.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., MiRNA-based treatment for Alzheimer’s Disease: MiRNA-4723 decreases HDAC2 levels and increases the expression of synaptic genes via down regulation of its target gene, 17/September/2014, 11.45 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation